GlassScriptPhysician profile
Sunbal Zafar
NPI 1225059009
$3,646.83
in general payments reported to CMS, 2019-2025
29 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $288 · 2021: $573 · 2022: $406 · 2023: $530 · 2024: $680 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855 · Education: $54.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.19 |
| Education | $54.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,127.05 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $452.28 | 2019-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $292.81 | 2019-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $191.82 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $170.81 | 2019-2021 | |
| Redhill Biopharma INC. | $157.11 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $153.51 | 2019-2023 | Entyvio |
| Evoke Pharma, INC. | $135.58 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $104.13 | 2021-2023 | |
| Celgene Corporation | $104.10 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $92.63 | 2020-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $84.77 | 2019-2024 | |
| Qol Medical, LLC | $84.11 | 2022-2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $72.97 | 2019-2024 | |
| Allergan, INC. | $53.52 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $47.23 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $44.67 | 2021-2023 | Dificid |
| Fresenius Kabi USA, LLC | $36.90 | 2023 | Idacio |
| Pfizer INC. | $34.02 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $32.78 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $32.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $25.91 | 2024 | |
| Ardelyx, INC. | $24.09 | 2023 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $18.42 | 2019 | |
| Lilly USA, LLC | $18.28 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.37 | 2023 | |
| Aimmune Therapeutics, INC. | $16.05 | 2025 | Zenpep |
| Cumberland Pharmaceuticals, INC. | $13.55 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $7.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunbal Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.